Brompheniramine

As allergic diseases fall into the category of chronic diseases with high global incidence, antihistamines have always been the core option for clinical symptomatic treatment. Brompheniramine belongs to the first-generation propylamine H1 receptor antagonists. By competitively blocking the binding of histamine to H1 receptors on effector cells, it effectively inhibits the pathological reactions caused by histamine, such as capillary dilatation, smooth muscle spasm, and increased vascular permeability. Clinically, it is mainly used for the treatment of allergic diseases such as allergic rhinitis, urticaria, and hay fever. As its sedative effect is weaker than that of other first-generation antihistamines, it is suitable for patients who need to control allergic symptoms and are relatively sensitive to central inhibitory reactions.

At present, the global market size of antihistamines has exceeded 10 billion US dollars. Among them, first-generation antihistamines still maintain stable demand in primary medical care and OTC markets due to their high cost-effectiveness and long clinical application history. As a classic variety, brompheniramine maintains a steady annual market demand growth rate of around 3%. The domestic market is currently dominated by generic drug supplies. There are 3 enterprises holding the approval documents for brompheniramine preparations, and the localization rate of active pharmaceutical ingredients (APIs) has reached more than 90%. It has not been included in the national centralized volume procurement catalog, and the market competition pattern is relatively stable.

The original research enterprise of brompheniramine is Bayer Pharma, and the original research brand name is Dimetapp. The core compound patent expired globally in 1986. At present, the mainstream dosage forms include tablets (4mg) and oral solutions (2mg/5ml). Its 4mg tablet has been included in the FDA Reference Listed Drug catalog, while the original research product has not yet been included in the domestic reference listed drug catalog. Currently, there is no publicly announced A-state registration number for brompheniramine API in China, and a total of 2 enterprises hold the marketing approval numbers for brompheniramine tablets.(Data as of October 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for brompheniramine API. Most products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. All products fully comply with the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable reference material support for pharmaceutical enterprises in API R&D, quality research and declaration work.

CATO/佳途科技可提供溴苯那敏原料药全套杂质标准品，大部分产品现货供应，现货产品16:00前下单当天发货，全面符合中国药典、FDA等多法规体系的合规要求，能够为药企的原料药研发、质量研究及申报工作提供稳定的标准物质支撑。